Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.56 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.46 |
| ▸ | HSD11B1 known ✓ | P28845 | 6/20 | 0.45 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.44 |
| ▸ | TET3 | O43151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.52 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.52 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.52 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.52 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4005636 | 0.98 | DRD2 (0.58) | DRD2TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL27594934 | 0.86 | DRD2 (0.59) | DRD2TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL75310 | 0.85 | TET3 (0.61) | TET3KMT2AFBXL19CXXC5KDM2B | |
| Hydrochloric Acid SCHEMBL8353081 | 0.85 | DRD2 (0.54) | DRD2HDAC4HSD11B1OPRM1AKT1 | |
| Hydrochloric Acid SCHEMBL18281540 | 0.84 | AKR1C1 (0.66) | TET3KMT2AFBXL19CXXC5KDM2B | |
| Hydrochloric Acid SCHEMBL5741878 | 0.84 | AKR1C1 (0.66) | TET3KMT2AFBXL19CXXC5KDM2B | |
| Hydrochloric Acid SCHEMBL2552731 | 0.84 | AKR1C1 (0.66) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL652508 | 0.83 | DRD2 (0.56) | DRD2HDAC4HSD11B1OPRM1AKT1 | |
| Hydrochloric Acid SCHEMBL5916170 | 0.83 | APP (0.49) | AKR1C1HSD11B1OPRM1AKR1C3AKR1C2 | |
| SCHEMBL651440 | 0.83 | DRD2 (0.56) | DRD2HDAC4HSD11B1OPRM1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576218-B2 | 4-phenylpiperdine-pyrazole CCR1 antagonists | CHEMOCENTRYX, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| EP-1919875-A2 | PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS | Astex Therapeutics Limited (GB) | 2008-05-14 | — | — | EP | disclosed |
| EP-1814552-A2 | COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS | Astex Therapeutics Limited (GB) | 2007-08-08 | — | — | EP | disclosed |
| WO-2007073432-A2 | PIPERIDINE DERIVATIVES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070088036-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | US | disclosed |
| WO-2007044804-A2 | PIPERIDINE DERIVATIVES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2006136829-A2 | PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| US-20060128752-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
| WO-2006051290-A2 | COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| US-20050245572-A1 | Naphthyl ether compounds and their use | OLINK AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1558577-A2 | SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-08-03 | — | — | EP | disclosed |
| EP-1546101-A1 | NAPHTHYL ETHER COMPOUNDS AND THEIR USE | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004022539-A1 | NAPHTHYL ETHER COMPOUNDS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004005256-A2 | SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | CNKSR1, PRKCH, PRKAR2B | DRD2 3776/4885HDAC4 2455/4885HSD11B1 2425/4885 |
| US-20060128752-A1 | Chemical compounds | HTR7, NPSR1, TACR2 | DRD2 83/4885HDAC4 2510/4885HSD11B1 786/4885 |
| US-20070088036-A1 | Piperidine derivatives and methods of use | CCR1, CCR3, CCR4 | DRD2 613/4885HDAC4 838/4885HSD11B1 3343/4885 |
| US-20050245572-A1 | Naphthyl ether compounds and their use | NR4A1, NPM1, H1-4 | DRD2 1039/4885HDAC4 478/4885HSD11B1 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.